KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Investments (2017 - 2024)

Arbutus Biopharma (ABUS) has disclosed Long-Term Investments for 11 consecutive years, with $3.0 million as the latest value for Q3 2024.

  • Quarterly Long-Term Investments fell 71.76% to $3.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Sep 2024, down 71.76% year-over-year, with the annual reading at $6.3 million for FY2023, 83.18% down from the prior year.
  • Long-Term Investments hit $3.0 million in Q3 2024 for Arbutus Biopharma, down from $6.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $55.4 million in Q3 2022 to a low of $1.6 million in Q2 2020.
  • Historically, Long-Term Investments has averaged $23.9 million across 5 years, with a median of $31.8 million in 2023.
  • Biggest five-year swings in Long-Term Investments: crashed 88.87% in 2020 and later soared 2130.5% in 2021.
  • Year by year, Long-Term Investments stood at $1.6 million in 2020, then skyrocketed by 2130.5% to $35.7 million in 2021, then increased by 4.69% to $37.4 million in 2022, then crashed by 83.18% to $6.3 million in 2023, then tumbled by 52.83% to $3.0 million in 2024.
  • Business Quant data shows Long-Term Investments for ABUS at $3.0 million in Q3 2024, $6.5 million in Q2 2024, and $8.7 million in Q1 2024.